Invariant natural killer T cell-based immunotherapy for cancer (Q37773278)

22 August 2017

1 reference

title

Invariant natural killer T cell-based immunotherapy for cancer (English)

1 reference

22 August 2017

1 reference

Shinichiro Motohashi

1

1 reference

22 August 2017

Toshinori Nakayama

series ordinal

2

1 reference

22 August 2017

publication date

1 January 2009

1 reference

22 August 2017

1 reference

22 August 2017

volume

1

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

73-82

1 reference

The regulatory role of Valpha14 NKT cells in innate and acquired immune response.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

CD1: antigen presentation and T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

21 January 2018

The biology of NKT cells

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Toward an understanding of NKT cell biology: progress and paradoxes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

NKT cells: T lymphocytes with innate effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Recognition of bacterial glycosphingolipids by natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

The immunoregulatory role of CD1d-restricted natural killer T cells in disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Loss of IFN-gamma production by invariant NK T cells in advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Glycolipid antigen induces long-term natural killer T cell anergy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Expansion of lung V alpha 14 NKT cells by administration of alpha-galactosylceramide-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Migration of tumor antigen-pulsed dendritic cells after mucosal administration in the human upper respiratory tract.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Differential antitumor immunity mediated by NKT cell subsets in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

In vitro expanded human invariant natural killer T-cells promote functional activity of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Distinct functional lineages of human V(alpha)24 natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Clinical applications of natural killer T cell-based immunotherapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

Cross-presentation of disialoganglioside GD3 to natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.73

21 January 2018

Identifiers

DOI

10.2217/1750743X.1.1.73

1 reference

22 August 2017

1 reference